Bharat Biotech's Covaxin is safe for children between 2 and 18 yrs: Lancet

Data from over 50 million doses reveals minimal side effects

Bharat Biotech's Covaxin has proved to be safe, well-tolerated and immunogenic in the paediatric population in Phase-II and -III studies, according to a study published in the peer-reviewed journal The Lancet.

Bharat Biotech has a stockpile of more than 50 million doses of Covaxin ready to be distributed as required.

The company claimed that Covaxin is one of the first Covid-19 vaccines in the world to generate data in the 2-18 year age group. Data from over 50 million doses given to children in India reveals minimal side effects. This data is now peer-reviewed and published in The Lancet Infectious